Epigral Reports Q4FY25 PAT Growth of 13% to Rs 870 Million

07 May 2025 CW Team

Reflecting its strong performance, the company’s balance sheet strengthened further in FY25. Return on capital employed (ROCE) rose to 25% from 18% in FY24, and Net Debt/EBITDA improved significantly to 0.7x from 2.0x. Credit rating was upgraded to CRISIL AA from CRISIL AA-.

Chairman and Managing Director Maulik Patel stated, “We closed FY2025 with the highest-ever revenue of Rs 25.65 billion, a 33% growth over the previous year. This was driven by an 11% volume increase, especially in high-value products. Our Derivatives & Specialty segment grew 24% and now contributes 54% to total revenue, up from 45% in FY24.”

The company plans to expand its CPVC and Epichlorohydrin (ECH) capacities, which are expected to come online in H1FY27 and contribute thereafter. The integrated complex is expected to further benefit once these projects reach full capacity.

Dividend Update:

Epigral’s board proposed a final dividend of Rs 3.5 per equity share, bringing the total dividend for FY2025 to Rs 6.0 per share (60% of the face value of Rs 10).

Strategic & financial highlights for FY2025:

Credit rating upgraded to CRISIL AA.
Capital expenditure stood at Rs 1.95 billion in FY2025.
Successfully raised Rs 3.33 billion via QIP to support growth.
CPVC Resin capacity expanded to 75,000 TPA; approved to double to 150,000 TPA.
Epichlorohydrin capacity to double to 100,000 TPA.
Commissioned CPVC Compound and Chlorotoluenes Value Chain facilities.

Q4FY25 operational & financial highlights:

Revenue grew 20% YoY to Rs 6.31 billion.
Derivatives & Specialty segment’s revenue contribution rose to 52% from 48% in Q4FY24.
EBITDA increased 12% to Rs 1.73 billion, with a margin of 28%.
PAT rose 13% to Rs 870 million.
Captive chlorine usage increased to 76%.

FY2025 operational & financial summary:

Sales volume grew 11%, with overall capacity utilisation at 81% (vs 78% in FY24).
Highest-ever revenue at Rs 25.65 billion, up 33% YoY.
Derivatives & Specialty business contributed 54% to revenue.
EBITDA rose 48% to Rs 7.11 billion (vs Rs 4.81 billion in FY24).
EBITDA margin improved to 28% from 25%.
PAT surged 82% to Rs 3.57 billion.

(BSE)

Image Source: Image Generated by ChatGPT

Epigral Limited, a leading integrated chemical manufacturer in India, announced its financial results for the quarter ended March 31, 2025. The company reported a 13% year-on-year rise in profit after tax (PAT) at Rs 870 million in Q4FY25, compared to Rs 770 million in Q4FY24. Revenue for the quarter stood at Rs 6.31 billion, up 20% from Rs 5.26 billion in the same quarter last year.Reflecting its strong performance, the company’s balance sheet strengthened further in FY25. Return on capital employed (ROCE) rose to 25% from 18% in FY24, and Net Debt/EBITDA improved significantly to 0.7x from 2.0x. Credit rating was upgraded to CRISIL AA from CRISIL AA-.Chairman and Managing Director Maulik Patel stated, “We closed FY2025 with the highest-ever revenue of Rs 25.65 billion, a 33% growth over the previous year. This was driven by an 11% volume increase, especially in high-value products. Our Derivatives & Specialty segment grew 24% and now contributes 54% to total revenue, up from 45% in FY24.”The company plans to expand its CPVC and Epichlorohydrin (ECH) capacities, which are expected to come online in H1FY27 and contribute thereafter. The integrated complex is expected to further benefit once these projects reach full capacity.Dividend Update:Epigral’s board proposed a final dividend of Rs 3.5 per equity share, bringing the total dividend for FY2025 to Rs 6.0 per share (60% of the face value of Rs 10).Strategic & financial highlights for FY2025:Credit rating upgraded to CRISIL AA.Capital expenditure stood at Rs 1.95 billion in FY2025.Successfully raised Rs 3.33 billion via QIP to support growth.CPVC Resin capacity expanded to 75,000 TPA; approved to double to 150,000 TPA.Epichlorohydrin capacity to double to 100,000 TPA.Commissioned CPVC Compound and Chlorotoluenes Value Chain facilities.Q4FY25 operational & financial highlights:Revenue grew 20% YoY to Rs 6.31 billion.Derivatives & Specialty segment’s revenue contribution rose to 52% from 48% in Q4FY24.EBITDA increased 12% to Rs 1.73 billion, with a margin of 28%.PAT rose 13% to Rs 870 million.Captive chlorine usage increased to 76%.FY2025 operational & financial summary:Sales volume grew 11%, with overall capacity utilisation at 81% (vs 78% in FY24).Highest-ever revenue at Rs 25.65 billion, up 33% YoY.Derivatives & Specialty business contributed 54% to revenue.EBITDA rose 48% to Rs 7.11 billion (vs Rs 4.81 billion in FY24).EBITDA margin improved to 28% from 25%.PAT surged 82% to Rs 3.57 billion.(BSE)Image Source: Image Generated by ChatGPT

Infrastructure Urban

17 Sep 2025

DCPC Prepares for Special Campaign 5.0 with Focus on E-Waste

The Department of Chemicals and Petrochemicals (DCPC), Ministry of Chemicals and Fertilisers, is gearing up for Special Campaign 5.0, to be held from 2nd to 31st October 2025. The initiative will focus on e-waste disposal as per MoEFCC’s E-Waste Management Rules 2022, space optimisation, and enhancing workplace efficiency across field offices.Special Campaign 4.0, conducted between October 2023 and October 2024, delivered notable results in record management, grievance redressal, scrap disposal, and cleanliness drives.Key outcomes of Special Campaign 4.0Records management: 2,443 physical fil..

Real Estate

17 Sep 2025

BlackRock India Leases 1.4 Lakh Sq Ft in Bengaluru

BlackRock Services India, the domestic arm of global asset manager BlackRock, has leased 1.4 lakh sq ft of office space at IndiQube Symphony in Bengaluru, according to Propstack data. The 10-year deal is valued at around Rs 4.10 billion.The lease, among the largest transactions in India’s co-working sector, highlights the growing preference of global institutions for flexible office providers. The agreement, commencing October 1, 2025, covers ground plus five floors in KNG Tower 1 at Ashoknagar, MG Road — one of Bengaluru’s prime commercial hubs.As per the lease document, BlackRock will ..

Infrastructure Transport

17 Sep 2025

L&T Bags Rs 25–50 Bn Order for Mumbai-Ahmedabad Bullet Train Track Works

Larsen & Toubro’s (L&T) Transportation Infrastructure business has secured an order valued between Rs 25 crore and Rs 50 billion from the National High Speed Rail Corporation Limited (NHSRCL) for the Mumbai-Ahmedabad High Speed Rail (MAHSR) corridor.The contract, Package T1, involves the design, supply, construction, testing, and commissioning of 156 route km of high-speed ballastless track on a Design-Build Lump Sum Price basis. The stretch runs from Mumbai’s Bandra-Kurla Complex to Zaroli village in Gujarat and includes 21 km of underground track and 135 km of elevated viaduct.Se..